IRWD, RXRX, NVAX, VTRS and NTLA gear up for earnings as the Medical sector posts solid sales growth despite a slight profit ...

The loss of market exclusivity for a trio of big-selling drugs in the last quarter of 2025 dragged down Novartis sales, but chief executive Vas Narasimhan says the company is equipped to ride out "the ...

Sweden’s Sobi has added another already-marketed product to its rare disease portfolio via a $29 per share takeover of Dova Pharmaceuticals. The deal – valued at up to $915 million – is due to ...

Over the past years, I have closely followed the evolution of the global oncology industry. What I have observed is steady, ...